Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.57 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.57 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.47 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.47 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19253605 | 0.89 | LRRK2 (0.63) | LRRK2SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL19253695 | 0.86 | NPC1 (0.59) | LRRK2SMN1; SMN2HSD17B1HSD17B2MEN1 | |
| SCHEMBL19270398 | 0.85 | LRRK2 (0.55) | TAS1R3TAS1R1TAS1R2LRRK2SMN1; SMN2 | |
| SCHEMBL19253774 | 0.82 | LRRK2 (0.61) | LRRK2SMN1; SMN2HSD17B1HSD17B2MEN1 | |
| SCHEMBL19253737 | 0.80 | LRRK2 (0.44) | LRRK2SMN1; SMN2HSD17B1HSD17B10MEN1 | |
| SCHEMBL19253738 | 0.80 | MEN1 (0.45) | LRRK2SMN1; SMN2HSD17B1HSD17B10MEN1 | |
| SCHEMBL24729258 | 0.79 | HSD17B10 (0.77) | TAS1R3TAS1R1TAS1R2LRRK2SMN1; SMN2 | |
| SCHEMBL29947688 | 0.79 | HSD17B10 (0.77) | TAS1R3TAS1R1TAS1R2LRRK2SMN1; SMN2 | |
| SCHEMBL19253769 | 0.79 | SCD (0.63) | LRRK2SMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL19253623 | 0.78 | RAF1 (0.43) | LRRK2SMN1; SMN2HSD17B1HSD17B2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10420753-B2 | Combination therapies for treatment of spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| US-10420753-B2 | Combination therapies for treatment of spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180235943-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-08-23 | — | — | US | disclosed |
| US-9895358-B2 | Combination therapies for treatment of spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-02-20 | — | — | US | disclosed |
| US-9895358-B2 | Combination therapies for treatment of spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-02-20 | — | — | US | disclosed |
| WO-2017147312-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170239225-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-08-24 | — | — | US | disclosed |
| US-20170239225-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235943-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MUSK, MYOF | TAS1R3 3945/4885TAS1R1 4073/4885TAS1R2 3860/4885 |
| US-10420753-B2 | Combination therapies for treatment of spinal muscular atrophy | SMN1; SMN2, MUSK, MYOF | TAS1R3 3945/4885TAS1R1 4073/4885TAS1R2 3860/4885 |
| US-20170239225-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MUSK, MYOF | TAS1R3 3945/4885TAS1R1 4073/4885TAS1R2 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.